Custom Health Holdings Inc. to Commence Trading on the Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - Custom Health Holdings Inc. (TSX: CHLT) (formerly, Queue Ventures Ltd.) ("Custom Health" or the "Company"), further to its press release dated June 5, 2026, is pleased to announce that it has received final approval for listing on the Toronto Stock Exchange (the "TSX"). The common shares of the Company (CUSIP 23204J104 / ISIN CA23204J1049) ("Common Shares") will commence trading on the TSX un
Technology, Pharmaceuticals, Health
2026-06-22 5:45 PM EDT | Custom Health Holdings Inc.
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000,000 convertible debenture financing ("Debenture" or "Financing"). The Debenture will fund the remaining IND-enabling work on the Company's lead candidate, BETR-001, as BetterLife sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache
2026-06-22 8:00 AM EDT | BetterLife Pharma Inc.
Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)
Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Yellowbird Diagnostics Inc. today announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation. Led by Dr. Benjamin Chow, the study enrolled twelve healthy volunteers,
Biotechnology, Pharmaceuticals
2026-06-22 7:51 AM EDT | Yellowbird Diagnostics
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operatio
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-22 7:00 AM EDT | Cannabis Bioscience International Holdings
Neural Therapeutics Inc. Announces Transition to Semi-Annual Financial Reporting
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators ("CSA"), the pilot program under
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-06-19 12:16 PM EDT | Neural Therapeutics Inc.
Richards Group Inc. Announces June 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended June 30, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on June 30, 2026 and will be payable on July 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends a
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-06-19 11:14 AM EDT | Richards Group Inc.
BioHarvest Sciences to Present at the 2026 BIO International Convention
British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details:
Biotechnology, Pharmaceuticals, Health
2026-06-18 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-18 7:00 AM EDT | Phio Pharmaceuticals Corp.
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. "These data reinforce
Biotechnology, Pharmaceuticals
2026-06-18 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Hemostemix' $1,000,000 Private Placement and Update
Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $
Biotechnology, Pharmaceuticals, Health
2026-06-17 5:22 PM EDT | Hemostemix Inc.
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, an
Biotechnology, Pharmaceuticals, Health
2026-06-17 3:15 AM EDT | Defence Therapeutics Inc.
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-16 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Telescope Innovations Provides Financial Results of Third Fiscal Quarter 2026
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE:J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended May 31, 2026 (Q3 FY2026). The Company generated revenues of approximately $2.1 million during this period, driven by a combination of contract services and Self-D
Technology, Chemical, Pharmaceuticals
2026-06-16 8:00 AM EDT | Telescope Innovations Corp.
Herbal Dispatch Provides Update on Domestic Retail Operations and Proprietary Brand Expansion
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, is pleased to provide an update on the continued growth of its domestic retail operations and expanding portfolio of proprietary cannabis brands. As part of its strategy to increase exposure to higher-margin branded products and build lon
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-06-16 3:01 AM EDT | Herbal Dispatch Inc.
Extendicare Announces June 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - June 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of June 2026, which is payable on July 15, 2026 to shareholders of record at the close of business on June 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare i
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-15 8:00 AM EDT | Extendicare Inc.
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery. PTSD affects veterans, first responde
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-15 7:00 AM EDT | Cannabis Bioscience International Holdings
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-15 7:00 AM EDT | Elite Pharmaceuticals, Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units
Biotechnology, Pharmaceuticals, Health
2026-06-12 5:39 PM EDT | PreveCeutical Medical Inc.
Bachem Holding AG Announces Capital Markets Day 2026
Bubendorf, Switzerland--(Newsfile Corp. - June 12, 2026) - Bachem Holding AG (SIX: BANB) will host its Capital Markets Day on 26 November 2026 at The Circle Convention Center, Hyatt Regency Zurich Airport, as well as virtually. This hybrid event will provide insights into the company's strategic priorities, business outlook, and key developments.
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-06-12 11:47 AM EDT | Bachem Holding AG
Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equity interest in CWE European Holdings Inc. ("CWE") not already owned by the Company, through a series of ancillary transa
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-06-12 7:30 AM EDT | Neural Therapeutics Inc.